The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy

In the last decade, an impressive advance was achieved in adoptive cell therapy (ACT), which has improved therapeutic potential and significant value in promising cancer treatment for patients. The ACT is based on the cell transfer of dendritic cells (DCs) and/or immune effector cells. DCs are often...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elena V. Abakushina, Liubov I. Popova, Andrey A. Zamyatnin, Jens Werner, Nikolay V. Mikhailovsky, Alexandr V. Bazhin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cancer immunotherapy adoptive cell therapy cancer vaccines dendritic cells tumor antigens NK cells Medicine R
Acceso en línea:	https://doaj.org/article/81a28abc7b514f69917fa462aecbcb95
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:81a28abc7b514f69917fa462aecbcb95
record_format	dspace
spelling	oai:doaj.org-article:81a28abc7b514f69917fa462aecbcb952021-11-25T19:11:39ZThe Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy10.3390/vaccines91113632076-393Xhttps://doaj.org/article/81a28abc7b514f69917fa462aecbcb952021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1363https://doaj.org/toc/2076-393XIn the last decade, an impressive advance was achieved in adoptive cell therapy (ACT), which has improved therapeutic potential and significant value in promising cancer treatment for patients. The ACT is based on the cell transfer of dendritic cells (DCs) and/or immune effector cells. DCs are often used as vaccine carriers or antigen-presenting cells (APCs) to prime naive T cells ex vivo or in vivo. Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are used as major tool effector cells for ACT. Despite the fact that NK cell immunotherapy is highly effective and promising against many cancer types, there are still some limitations, including insignificant infiltration, adverse conditions of the microenvironment, the immunosuppressive cellular populations, and the low cytotoxic activity in solid tumors. To overcome these difficulties, novel methods of NK cell isolation, expansion, and stimulation of cytotoxic activity should be designed. In this review, we discuss the basic characteristics of DC vaccines and NK cells as potential adoptive cell preparations in cancer therapy.Elena V. AbakushinaLiubov I. PopovaAndrey A. ZamyatninJens WernerNikolay V. MikhailovskyAlexandr V. BazhinMDPI AGarticlecancer immunotherapyadoptive cell therapycancer vaccinesdendritic cellstumor antigensNK cellsMedicineRENVaccines, Vol 9, Iss 1363, p 1363 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cancer immunotherapy adoptive cell therapy cancer vaccines dendritic cells tumor antigens NK cells Medicine R
spellingShingle	cancer immunotherapy adoptive cell therapy cancer vaccines dendritic cells tumor antigens NK cells Medicine R Elena V. Abakushina Liubov I. Popova Andrey A. Zamyatnin Jens Werner Nikolay V. Mikhailovsky Alexandr V. Bazhin The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
description	In the last decade, an impressive advance was achieved in adoptive cell therapy (ACT), which has improved therapeutic potential and significant value in promising cancer treatment for patients. The ACT is based on the cell transfer of dendritic cells (DCs) and/or immune effector cells. DCs are often used as vaccine carriers or antigen-presenting cells (APCs) to prime naive T cells ex vivo or in vivo. Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are used as major tool effector cells for ACT. Despite the fact that NK cell immunotherapy is highly effective and promising against many cancer types, there are still some limitations, including insignificant infiltration, adverse conditions of the microenvironment, the immunosuppressive cellular populations, and the low cytotoxic activity in solid tumors. To overcome these difficulties, novel methods of NK cell isolation, expansion, and stimulation of cytotoxic activity should be designed. In this review, we discuss the basic characteristics of DC vaccines and NK cells as potential adoptive cell preparations in cancer therapy.
format	article
author	Elena V. Abakushina Liubov I. Popova Andrey A. Zamyatnin Jens Werner Nikolay V. Mikhailovsky Alexandr V. Bazhin
author_facet	Elena V. Abakushina Liubov I. Popova Andrey A. Zamyatnin Jens Werner Nikolay V. Mikhailovsky Alexandr V. Bazhin
author_sort	Elena V. Abakushina
title	The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
title_short	The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
title_full	The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
title_fullStr	The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
title_full_unstemmed	The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
title_sort	advantages and challenges of anticancer dendritic cell vaccines and nk cells in adoptive cell immunotherapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/81a28abc7b514f69917fa462aecbcb95
work_keys_str_mv	AT elenavabakushina theadvantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT liubovipopova theadvantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT andreyazamyatnin theadvantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT jenswerner theadvantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT nikolayvmikhailovsky theadvantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT alexandrvbazhin theadvantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT elenavabakushina advantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT liubovipopova advantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT andreyazamyatnin advantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT jenswerner advantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT nikolayvmikhailovsky advantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy AT alexandrvbazhin advantagesandchallengesofanticancerdendriticcellvaccinesandnkcellsinadoptivecellimmunotherapy
_version_	1718410167071014912

The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy

Ejemplares similares